

Evolution of Immunotherapy and the Road Ahead in HNSCC

Monday, 22 October 2018
18:30 – 20:00

Satellite Symposium
Sponsored by MSD

Messe Munich
Hall B3 – Room 22
Munich, Germany

Chair: Viktor Grünwald (Germany)

CHAIR

Viktor Grünwald

Professor for Hematology and Oncology
Department of Hematology, Hemostasis,
Oncology, and Stem Cell Transplantation
Medical School Hannover (MHH)
Hannover, Germany

FACULTY

Barbara Burtress

Clinical Research Program Leader
Head and Neck Cancers Program
Co-Director, Developmental
Therapeutics Research Program
Professor of Medicine (Medical
Oncology)
Yale Cancer Center
New Haven, Connecticut, USA

Ezra Cohen

Professor of Medicine
University of California, San Diego
Moore's Cancer Center
San Diego, California, USA

Educational Objectives

- Generate awareness and educate on the latest advances in checkpoint inhibition–based immunotherapy and the unmet needs in R/M HNSCC
- Educate on the rationale for monotherapy and combination therapy and the future of combination strategies in the treatment of patients with R/M HNSCC

AGENDA

18:30 – 18:35	Welcome and Introduction	Viktor Grünwald
18:35 – 18:45	Overview of Treatment Options in Recurrent/Metastatic (R/M) HNSCC	Viktor Grünwald
18:45 – 19:00	Maximizing Treatment Outcomes for Patients With R/M HNSCC	Viktor Grünwald
19:00 – 19:20	Debate: Monotherapy or Combination Immunotherapy in R/M HNSCC? (Part 1: Monotherapy)	Barbara Burtress
19:20 – 19:40	Debate: Monotherapy or Combination Immunotherapy in R/M HNSCC? (Part 2: Combination)	Ezra Cohen
19:40 – 20:00	Q&A and Closing Remarks	Chair and Expert Panel